Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Multicenter Double-Blind Group-Sequential Study to Evaluate the Efficacy Immunogenicity and Safety of a Single Dose of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery

Next Previous
X
Search
Trial Profile

A Randomized Multicenter Double-Blind Group-Sequential Study to Evaluate the Efficacy Immunogenicity and Safety of a Single Dose of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V-710 (Primary)
  • Indications Mediastinitis; Staphylococcal infections; Surgical wound infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 19 Jun 2019 This trial has been discontinued in France, according to European Clinical Trials Database.
    • 03 Apr 2013 Primary endpoint 'Vaccine-protective-efficacy' has not been met.
    • 03 Apr 2013 Results published in JAMA: the Journal of the American Medical Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top